Immunoproliferative Disorders  >>  epirubicin  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
epirubicin / Generic mfg.
ANZINTER3, NCT01148446: R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL

Completed
3
226
Europe
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Epirubicin, Vinblastine, Rituximab, G-CSF
Fondazione Italiana Linfomi ONLUS
Elderly Patients (>65 Years), Diffuse Large B Cell Lymphoma (DLBCL)
01/06
 
DSMM-II, NCT02288741: Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy

Completed
3
549
Europe
Anthracycline/dexamethasone-based induction chemotherapy, ID, VAD, CAD, Dexamethasone for control of symptoms, dexamethasone, Tumor-reduction chemotherapy and stem cell mobilization, IEV + G-CSF, Stem cell apheresis, SC-apheresis, Tandem high-dose chemotherapy (melphalan), Tandem melphalan, Autologous peripheral blood stem cell transplantation, PBSCT
WiSP Wissenschaftlicher Service Pharma GmbH
Multiple Myeloma
09/12
09/12
NCT00854568: Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL

Completed
3
398
RoW
CEOP regimen, CEOP, CHOP regimen, CHOP
Fudan University
Lymphoma
12/12
02/13

Download Options